The hematologist-oncogeneticist and founder of Truvexa Health Private Limited is bringing oncology, genetics, precision medicine and rehabilitation into a single conversation.
When Dr. Farheen ZuberMohmed talks about cancer, she does not begin with a tumour. She begins with the person sitting across from her.It is a perspective that has shaped her medical career—and eventually led her to establish Truvexa Health Private Limited.A hematologist-oncogeneticist working in hematologic malignancies, cancer genetics, precision oncology and translational research, Dr. Farheen has built her professional interests around a part of medicine that is becoming increasingly complex: understanding cancer at a molecular level while not losing sight of the person experiencing it.For patients, that distinction can matter.A cancer diagnosis can raise questions that extend far beyond treatment. There may be concerns about hereditary risk, genetic testing, nutrition, emotional wellbeing, physical recovery, family members and what happens after active treatment ends.Those questions have increasingly influenced the way Dr. Farheen has shaped her work.The clinical services encompass clinical genetics, cancer genetic counselling, molecular and precision oncology, expert case reviews, multidisciplinary case discussions, psycho-oncology, onco-nutrition, rehabilitation and recovery, survivorship planning, caregiver support and cancer-care coordination.It is an approach that reflects a changing understanding of what cancer care involves.
Cancer Is More Than a DiagnosisModern oncology can now examine cancer at levels that were difficult to imagine only a few decades ago.Genomic testing can reveal molecular characteristics of disease. Advances in pathology and molecular biology are providing increasingly detailed information about tumour behaviour. Treatment decisions can, in appropriate circumstances, incorporate this information.But precision medicine has another dimension.A molecular report does not describe the whole person.Dr. Farheen’s approach places the biological information alongside the patient’s clinical history, hereditary background and circumstances. In that sense, precision is not simply about obtaining more data; it is about understanding what that information means in context.
The Family QuestionThat becomes particularly important when genetics enters the picture.Cancer can sometimes have an inherited component, making genetic assessment relevant not only to the individual but also to relatives.Hereditary cancer risk assessment and cancer genetic counselling form part of the services offered, with attention to helping individuals understand their family history, potential hereditary risk and the implications of genetic information.For Dr. Farheen, the laboratory result is only one part of the conversation.The harder—and often more important—question is what that result means for a person and their family.
Where Research Meets MedicineThe next chapter of her work extends into research.Plans include capabilities involving next-generation sequencing, single-cell transcriptomics, spatial biology, proteomics and AI-supported predictive oncology research.Each represents a rapidly developing area of cancer science, offering researchers increasingly detailed ways of studying disease.But Dr. Farheen’s interest lies beyond technological novelty.The central question is translation: how discoveries made through advanced research can eventually become clinically useful.That emphasis reflects her interest in translational oncology, where laboratory science and patient care meet.
What Happens After Treatment?There is another question that can be overlooked amid discussions of cutting-edge cancer treatment: what happens when treatment is over?For many patients, the answer is not an immediate return to normal life.Fatigue, nutritional problems, reduced physical function, psychological distress and uncertainty can persist. Families and caregivers can face their own challenges.This is where rehabilitation and recovery, nutrition and lifestyle support, psycho-oncology, caregiver counselling, palliative support and survivorship planning become relevant.For Dr. Farheen, recovery is not separate from cancer care. It is part of the story.
From Ahmedabad to a Wider VisionThe work is being developed from India, with plans extending into the UAE.The vision associated with GIFT City, Gandhinagar includes advanced cancer research, molecular diagnostics, precision oncology and rehabilitation, while the UAE development encompasses integrated rehabilitation, transitional care and concierge medical services.The geographical expansion is accompanied by an equally broad scientific ambition: to create a setting in which specialised clinical expertise can coexist with emerging areas of cancer research.
Four Words That Capture the DirectionThe philosophy behind the work can be distilled into four ideas:Care. Precision. Research. Rehabilitation.They represent different stages of the same larger journey—from understanding disease and making clinical decisions to helping patients recover and move forward.For Dr. Farheen, that journey is becoming increasingly important as oncology itself changes.
The Next Generation of Cancer CareThe future of cancer medicine is unlikely to be defined by one discipline alone.Genomics will continue to influence how disease is understood. Molecular diagnostics will become more sophisticated. Research will probe cancer biology at ever finer levels. Rehabilitation and survivorship will remain important long after active treatment.The challenge will be bringing these advances together without losing sight of the individual patient.That is the space Dr. Farheen ZuberMohmed is working in.Through Truvexa Health, she is building on a belief that has remained consistent throughout her approach to cancer care: the more precisely medicine understands the disease, the more carefully it should understand the person living with it.
Truvexa Health Private Limited
Advanced Cancer Care. Research. Rehabilitation. Built in India. Benchmarked to the world.
